Bispecific antibodies specific for PD1 and TIM3

US12391757B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Laura Codarri-Deak · Schlieren, CH
• Georg Fertig · Penzberg, DE
• Jens Fischer · Penzberg, DE
• Christian Klein · Iffeldorf, DE
• Viktor Levitski · Schlieren, CH
• Valeria Lifke · Penzberg, DE
• Mario Perro · Schlieren, CH
• Joerg Thomas Regula · Munich, DE
• Tilman Schlothauer
• Stefan Seeber · Penzberg, DE
• Pablo Umana · Wollerau, CH
• Ildiko Wuensche · Penzberg, DE
• Adrian Zwick · Penzberg, DE

Key dates

• Filing date: Sep 3, 2021
• Grant date: Aug 19, 2025
• Expiry date: Sep 12, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.